5-Fluorouracil (Standard)

5-Fluorouracil (Standard) is the analytical standard of 5-Fluorouracil. This product is intended for research and analytical applications. 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].

Product Specifications

CAS Number

[51-21-8]

Product Name Alternative

5-FU (Standard)

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H335, H361, H412

Target

Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/5-fluorouracil-standard.html

Purity

99.83

Smiles

O=C(N1)NC=C(F)C1=O

Molecular Formula

C4H3FN2O2

Molecular Weight

130.08

Precautions

H301, H315, H319, H335, H361, H412

References & Citations

[1]Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print]|[2]McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28.|[3]Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418 (1-2) :137-46.|[4]Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130.|[5]Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul;45 (7) :941-948.|[6]Snyder SM, et al. Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia. J Int Assoc Physicians AIDS Care (Chic) . 2011;10 (2) :83-88.|[7]Pek Yee Lum, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004 Jan 9;116 (1) :121-37.